<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62185">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049736</url>
  </required_header>
  <id_info>
    <org_study_id>Telbivudine for CKD</org_study_id>
    <nct_id>NCT02049736</nct_id>
  </id_info>
  <brief_title>The Effect of Telbivudine on Renal Function and Proteinuria in Patients With Chronic Hepatitis B Infection and Chronic Kidney Diseases</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <authority>Hong Kong: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) and chronic viral hepatitis due to hepatitis B virus (HBV) are
      both major public health problems. Treatment of chronic HBV infection in CKD patients,
      however, is not well defined because of insufficient data from clinical trials. Telbivudine
      is a new antiviral that provides effective and sustained viral suppression in patients with
      compensated chronic hepatitis B infection. Unlike other nucleotide and nucleoside analogues,
      renal toxicity is uncommon in telbivudine, and dosage adjustment is not required in patients
      with mild renal impairment. We propose to conduct an open-label single-arm study to evaluate
      the effect of telbivudine on renal function and proteinuria in patients with chronic HBV
      infection and mild-to-moderate renal impairment. Twenty patients with chronic HBV infection
      and chronic kidney disease (estimated glomerular filtration rate 15 to 60 ml/min) will be
      recruited. They will be treated with telbivudine, with the dosage adjusted according to thei
      renal function, for 5 years. Serum HBV DNA, proteinuria, renal function, and urinary
      inflammatory markers will be monitored.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease (CKD) is a major public health problem worldwide over the past few
      decades, partly because of the increasing prevalence of hypertension, diabetes mellitus, and
      elderly individuals in most countries. In southeast Asia, chronic viral hepatitis due to
      hepatitis B virus (HBV) also poses significant morbidity and mortality [2]. Chronic HBV
      infection can cause chronic glomerulonephritis and CKD. More importantly, patients with CKD,
      irrespective to the underlying renal diagnosis, who acquire HBV infection have higher
      morbidity and mortality rates, and the management of chronic HBV infections among CKD
      patients with antiviral agents is associated with a high risk of adverse effects. The
      optimal management of CKD associated with chronic HBV infection is not well defined because
      of insufficient data from clinical trials.

      Telbivudine (Sebivo®; Tyzeka®) is a synthetic nucleoside analogue that inhibits replication
      of HBV. Telbivudine is a potent antiviral that provides effective and sustained viral
      suppression in patients with compensated chronic hepatitis B infection, and is used in the
      treatment of adults with chronic hepatitis B with evidence of viral replication and
      persistently elevated serum transaminase levels, or histological evidence of active disease.
      Unlike most of the other nucleoside and nucleotide analogues, renal toxicity of telbivudine
      is uncommon, and dose adjustment is only necessary for patients with moderate to severe
      renal impairment. Recent data further suggest that telbivudine treatment may have a
      beneficial effect on renal function.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in estimated glomerular filtration rate</measure>
    <time_frame>every 3 months for 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>proteinuria</measure>
    <time_frame>every 3 months for 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA level</measure>
    <time_frame>every 6 months for 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Telbivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <arm_group_label>Telbivudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18-70 years

          -  hepatitis B surface antigen (HBsAg) positive

          -  clinical indication for antiviral therapy according to the Asian Pacific guideline
             [16]

          -  HBeAg positive, ALT &gt;2 times upper limit of normal AND HBV DNA &gt;20,000 IU/ml AND HBV
             DNA &lt;9 log10 copies/mL; OR

          -  HBeAg negative, ALT &gt;2 times upper limit of normal AND HBV DNA &gt;2,000 IU/ml AND HBV
             DNA &lt;7 log10 copies/mL; OR

          -  Evidence of advanced liver fibrosis or liver cirrhosis AND detectable HBV DNA

          -  estimated glomerular filtration rate (GFR) 15 to 60 ml/min/1.73m2

          -  willingness to give written consent and comply with the study protocol

        Exclusion Criteria:

          -  Pregnancy, lactating or childbearing potential without effective method of birth
             control

          -  Severe gastrointestinal disorders that interfere with their ability to receive or
             absorb oral medication

          -  History of malignancy, including leukemia and lymphoma within the past 2 years

          -  Active systemic infection.

          -  Any other severe coexisting disease such as, but not limited to, advanced liver
             cirrhosis, myocardial infarction, cerebrovascular accident, malignant hypertension

          -  History of drug or alcohol abuse within past 2 years

          -  Patients receiving antiviral therapy for chronic hepatitis B within the past 12
             months

          -  Patients receiving treatment of corticosteroid or other immunosuppressive / cytotoxic
             agents

          -  On other investigational drugs within last 3 months

          -  History of a psychological illness or condition such as to interfere with the
             patient's ability to understand the requirement of the study

          -  History of non-compliance

          -  Known history of sensitivity or allergy to telbivudine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Henry LY Chan, MD</last_name>
    <phone>(852)2632-2211</phone>
    <email>hlychan@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angel ML Chim, MD</last_name>
    <phone>(852)2632-4205</phone>
    <email>angelchim@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henry LY Chan, MD</last_name>
      <phone>(852)2632-2211</phone>
      <email>hlychan@cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Angel ML Chim, MSc</last_name>
      <phone>(852)2632 4205</phone>
      <email>angelchim@cuhk.edu.hk</email>
    </contact_backup>
    <investigator>
      <last_name>Vincent WS Wong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grace LH Wong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, Hostetter TH. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005 Jan;16(1):180-8. Epub 2004 Nov 24.</citation>
    <PMID>15563563</PMID>
  </reference>
  <reference>
    <citation>Chen J, Wildman RP, Gu D, Kusek JW, Spruill M, Reynolds K, Liu D, Hamm LL, Whelton PK, He J. Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years. Kidney Int. 2005 Dec;68(6):2837-45.</citation>
    <PMID>16316361</PMID>
  </reference>
  <reference>
    <citation>Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol. 2004 Mar-Apr;24(2):198-211. Epub 2004 Feb 25. Review.</citation>
    <PMID>14988643</PMID>
  </reference>
  <reference>
    <citation>Chacko EC, Surrun SK, Mubarack Sani TP, Pappachan JM. Chronic viral hepatitis and chronic kidney disease. Postgrad Med J. 2010 Aug;86(1018):486-92. doi: 10.1136/pgmj.2009.092775. Review.</citation>
    <PMID>20709771</PMID>
  </reference>
  <reference>
    <citation>Wong PN, Fung TT, Mak SK, Lo KY, Tong GM, Wong Y, Loo CK, Lam EK, Wong AK. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol. 2005 Nov;20(11):1641-51. Review.</citation>
    <PMID>16246180</PMID>
  </reference>
  <reference>
    <citation>London WT, Drew JS, Lustbader ED, Werner BG, Blumberg BS. Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. Kidney Int. 1977 Jul;12(1):51-8.</citation>
    <PMID>894916</PMID>
  </reference>
  <reference>
    <citation>Peters MG. Special populations with hepatitis B virus infection. Hepatology. 2009 May;49(5 Suppl):S146-55. doi: 10.1002/hep.22965.</citation>
    <PMID>19399810</PMID>
  </reference>
  <reference>
    <citation>Girndt M, Köhler H. Hepatitis B virus infection in hemodialysis patients. Semin Nephrol. 2002 Jul;22(4):340-50. Review.</citation>
    <PMID>12118399</PMID>
  </reference>
  <reference>
    <citation>Fabrizi F, Messa P, Basile C, Martin P. Hepatic disorders in chronic kidney disease. Nat Rev Nephrol. 2010 Jul;6(7):395-403. doi: 10.1038/nrneph.2010.37. Epub 2010 Apr 13. Review.</citation>
    <PMID>20386560</PMID>
  </reference>
  <reference>
    <citation>McKeage K, Keam SJ. Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs. 2010 Oct 1;70(14):1857-83. doi: 10.2165/11204330-000000000-00000. Review.</citation>
    <PMID>20836578</PMID>
  </reference>
  <reference>
    <citation>But DY, Yuen MF, Fung J, Lai CL. Safety evaluation of telbivudine. Expert Opin Drug Saf. 2010 Sep;9(5):821-9. doi: 10.1517/14740338.2010.507190. Review. PubMed PMID: 20662545.</citation>
    <PMID>20662545</PMID>
  </reference>
  <reference>
    <citation>Zhou XJ, Swan S, Smith WB, Marbury TC, Dubuc-Patrick G, Chao GC, Brown NA. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 2007 Dec;51(12):4231-5. Epub 2007 Sep 17.</citation>
    <PMID>17875994</PMID>
  </reference>
  <reference>
    <citation>Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA; Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007 Dec 20;357(25):2576-88.</citation>
    <PMID>18094378</PMID>
  </reference>
  <reference>
    <citation>Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J, Leung N, Samuel D, Hsu CW, Bao W, Lopez P, Avila C. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int. 2011 May;31(5):676-84. doi: 10.1111/j.1478-3231.2011.02490.x. Epub 2011 Mar 16.</citation>
    <PMID>21457439</PMID>
  </reference>
  <reference>
    <citation>Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70.</citation>
    <PMID>10075613</PMID>
  </reference>
  <reference>
    <citation>Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. Erratum in: Ann Intern Med. 2011 Sep 20;155(6):408.</citation>
    <PMID>19414839</PMID>
  </reference>
  <reference>
    <citation>Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis. 2008 May;51(5):724-31. Epub 2008 Apr 3.</citation>
    <PMID>18436082</PMID>
  </reference>
  <reference>
    <citation>Grubb A, Nyman U, Björk J, Lindström V, Rippe B, Sterner G, Christensson A. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem. 2005 Aug;51(8):1420-31. Epub 2005 Jun 16.</citation>
    <PMID>15961546</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Henry LY Chan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
